Eli Lilly's acquisition signals psychedelic drugs' return for mental health, offering a novel approach to rewiring neural connections. The US FDA has granted breakthrough designations for various compounds, creating a promising market potentially exceeding existing mental health drug sales. Challenges include separating treatment effects, addressing safety concerns (side effects, addiction), and distinguishing clinical from recreational use. While exciting, clearer biochemistry is crucial, acknowledging historical reasons for their prior withdrawal. Indian pharmaceutical companies have an opportunity in this emerging field.